While emerging conventional wisdom may state biopharmaceutical companies could see a boon as a result of the COVID-19 pandemic thanks to new treatment and vaccine opportunities, the sector may not come out on top.

Rosiglitazone was once a popular treatment for Type 2 diabetes, but it fell out of favor due to a variety of side effects.

The World Health Organization estimates that 82 million people will be affected by dementia by the year 2030—could maintaining a healthy heart be one way to keep such conditions at bay?

Testing all residents and staff at the nation’s nursing homes just once would collectively cost $440 million, according to data from the American Health Care Association and National Center of Assisted Living (AHCA/NCAL).

Cardiac cath labs can achieve significant radiation dose reductions through focused, collaborative quality improvement (QI) efforts, according to a new analysis published in Circulation: Cardiovascular Interventions.

The news came just weeks after the FDA warned against treating COVID-19 with hydroxychloroquine “outside of the hospital setting or a clinical trial” due to significant cardiovascular complications.

The Association of Black Cardiologists (ABC) has shared resources for patients and healthcare providers focused on COVID-19’s impact on black communities and other underserved patient populations.

Edwards Lifesciences’ PASCAL transcatheter valve repair system has gained CE mark approval for treating tricuspid regurgitation (TR).